These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
622 related articles for article (PubMed ID: 30449777)
41. Nivolumab-induced aplastic anemia: A case report and literature review. Comito RR; Badu LA; Forcello N J Oncol Pharm Pract; 2019 Jan; 25(1):221-225. PubMed ID: 28825374 [TBL] [Abstract][Full Text] [Related]
42. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214 [TBL] [Abstract][Full Text] [Related]
43. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. Hurkmans DP; Verhoeven JGHP; de Leur K; Boer K; Joosse A; Baan CC; von der Thüsen JH; van Schaik RHN; Mathijssen RHJ; van der Veldt AAM; Hesselink DA J Immunother Cancer; 2019 Jul; 7(1):182. PubMed ID: 31300068 [TBL] [Abstract][Full Text] [Related]
44. Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. Ikeda T; Yamaguchi H; Dotsu Y; Taniguchi H; Gyoutoku H; Senju H; Sakamoto N; Iwanaga S; Kuwatsuka Y; Fukuda M; Mukae H Thorac Cancer; 2018 Nov; 9(11):1522-1524. PubMed ID: 30253076 [TBL] [Abstract][Full Text] [Related]
45. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. Cooper DS; Meriggioli MN; Bonomi PD; Malik R J Neuromuscul Dis; 2017; 4(2):169-173. PubMed ID: 28505981 [TBL] [Abstract][Full Text] [Related]
46. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies. Fazal M; Prentice DA; Kho LK; Fysh E Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231 [TBL] [Abstract][Full Text] [Related]
47. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response. Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171 [TBL] [Abstract][Full Text] [Related]
48. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086 [No Abstract] [Full Text] [Related]
49. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071 [TBL] [Abstract][Full Text] [Related]
50. Nivolumab-induced myositis: A case report and a literature review. Bourgeois-Vionnet J; Joubert B; Bernard E; Sia MA; Pante V; Fabien N; Honnorat J; Streichenberger N J Neurol Sci; 2018 Apr; 387():51-53. PubMed ID: 29571871 [No Abstract] [Full Text] [Related]
51. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Ide M; Tanaka K; Sunami S; Asoh T; Maeyama T; Tsuruta N; Nakanishi Y; Okamoto I Thorac Cancer; 2018 Nov; 9(11):1519-1521. PubMed ID: 30152594 [TBL] [Abstract][Full Text] [Related]
52. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma. Belkaid S; Berger M; Nouvier M; Picard C; Dalle S Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155 [No Abstract] [Full Text] [Related]
53. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. Arai T; Harada K; Usui Y; Irisawa R; Tsuboi R J Dermatol; 2017 Aug; 44(8):975-976. PubMed ID: 27649838 [No Abstract] [Full Text] [Related]
54. Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report. Rochefort P; Roussel J; de la Fouchardière A; Sarabi M; Desseigne F; Guibert P; Cattey-Javouhey A; Mastier C; Neidhardt-Berard EM; de la Fouchardière C Immunotherapy; 2018 Aug; 10(10):831-835. PubMed ID: 30073896 [TBL] [Abstract][Full Text] [Related]
56. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report. Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163 [TBL] [Abstract][Full Text] [Related]
57. Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report. Jiang R; Xu L; Huang Y; Fang C; Guo H; Li S; Wu J; Du Z Pancreas; 2018 Sep; 47(8):e53-e54. PubMed ID: 30113432 [No Abstract] [Full Text] [Related]
58. Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma. Komatsu T; Konishi K; Aoshima M; Tokura Y; Nakamura K Jpn J Radiol; 2018 Dec; 36(12):712-718. PubMed ID: 30206802 [TBL] [Abstract][Full Text] [Related]
59. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma]. Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737 [TBL] [Abstract][Full Text] [Related]
60. An update on the safety of nivolumab for the treatment of advanced melanoma. Czarnecka AM; Rutkowski P Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]